SEBMF Physician is a Leading Researcher for Libido-Enhancing Drug for Women
Posted on Jun 5, 2015
Yesterday’s testimony before the Food and Drug Administration on ‘the little pink pill’ Flibanserin has been hailed by many as a milestone in gender biased pharmaceuticals addressing sexual drive and libido.
Sutter East Bay Medical Foundation OB/GYN, Risa Kagan, M.D., was on the committee of medical experts and was a Principal Investigator for the drug for pre-menopausal and post menopausal women. “There are currently no drugs approved for female sexual function (while there are 26 drugs approved for males). With this vote we are one step closer to having an approved option for women. We can have a safety discussion that is well informed, monitored and updated, as opposed to the quackery and off-label treatments patients currently resort to,” said Kagan.
The FDA’s joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee determined by an 18 to 6 vote that the benefit/risk profile of flibanserin approval of the new drug.
Dr. Kagan is an obstetrician-gynecologist on staff with Alta Bates Summit Medical Center. She has been in practice for 37 years. Congratulations to Dr. Kagan on her research efforts through Alta Bates Summit’s REDI (Jordan Research and Education Institute).